Sarepta (SRPT) volatility low into shares could have 'considerably more upside,' Barron's says

Sarepta (SRPT) share price recently doubled after a surprise FDA approval of its Duchenne muscular dystrophy drug Exondys 51, Sarepta could have "considerably more upside" when taking into account traditional biotech valuation metrics, Barron's says. Option implied volatility index mean is at 59, compared to its 52-week range of 67 to 399, according to Livevol.

You May Also Be Interested In

• Skechers USA (SKX) August 55 puts active
• Colgate-Palmolive (CL) April weekly option implied volatility into quarter results
• AbbVie (ABBV) April weekly option implied volatility into quarter results